Emend for Multiple-day Emetogenic Chemotherapy
Completed · Phase 2
Conditions studied: Nausea, Vomiting
In brief
The purpose of the study is to assess the effect of Emend (aprepitant) on nausea and vomiting associated with chemotherapy. Chemotherapy commonly causes nausea and vomiting and this affects patients' quality of life and attitudes toward treatment. Although nausea and vomiting associated with chemotherapy has been decreasing due to improved therapy, some patients will still experience this side effect. Therefore, new medications are needed to decrease the amount of nausea and vomiting patients have with chemotherapy. Emend (aprepitant) is a new medication used to treat nausea and vomiting with chemotherapy, but it has only been studied in patients receiving only one dose of chemotherapy that makes most people sick. However, there is little experience with this medication in patients receiving multiple days of chemotherapy that causes nausea and vomiting.
Key facts
- Study ID
- NCT00711555
- Run by
- University of Illinois at Chicago
- People needed
- 22
- Starts
- 2005-11-01
- Expected to finish
- 2009-01-01
- Last updated by the study team
- 2021-08-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects with a life expectancy > 3 months
- Subjects with an ECOG performance score < 3
- Subjects with access to a telephone for follow-up
- Subjects able to swallow tablets and capsules
You may not qualify if…
- Subjects who previously received aprepitant as prophylaxis for chemotherapy induced nausea and vomiting.
- Subjects with an allergy, hypersensitivity, or contraindication to aprepitant, dexamethasone, prochlorperazine or a serotonin receptor antagonist.
- Subject with uncontrolled diabetes or a concurrent illness/condition requiring chronic systemic steroids or pre-existing gastrointestinal pathology.
- Subjects with a history of excessive alcohol consumption.
- Women who are pregnant or lactating.
- Subjects with nausea at baseline or chronically using other antiemetic agent(s).
- Subjects currently receiving another investigational agent.
- Subjects taking a medication that can interact with aprepitant, including the following medications:
- warfarin
- oral contraceptives
- tolbutamide
- phenytoin
- midazolam
- ketoconazole
- rifampin
- paroxetine
- diltiazem
- Subjects with poor hepatic or renal function defined as AST > 3 x ULN, ALT > 3 x ULN, total bilirubin > 3 x ULN, alkaline phosphatase > 3 x ULN or serum creatinine >2 mg/dl measured within three months before starting chemotherapy.
- Subjects with hepatic metastases with AST > 5 x ULN, ALT > 5 x ULN, total bilirubin > 5 x ULN, alkaline phosphatase > 5 x ULN.
Where it is running
- University of Illinois Medical Center — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.